DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi renotubular syndrome 1 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi renotubular syndrome 1 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi renotubular syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glycine amidinotransferase (GATM) — GATM is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet orndrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3JDW · 2.4 Å · ligand L-ornithine (ORN). Experimental structure, not a prediction.
What the evidence adds up to
A 1991 case report describes a 2-year-old girl who developed Fanconi syndrome with phosphopenic rickets after multiagent chemotherapy that included high-dose iffosfamide for an embryonal sarcoma. The radiological and biochemical signs of rickets resolved after treatment with 25-OH vitamin D3 and phosphorus supplements. The authors state that monitoring of tubular function in children during and after ifosfamide treatment is mandatory.
A 2012 case report describes a severely disabled young girl who developed Fanconi syndrome secondary to long-term valproic acid administration, which led to hypophosphatemic rickets. The patient also presented with nephrocalcinosis, which the authors note is not a common feature in proximal tubulopathy, and they suggest that the concomitant use of another anticonvulsant might have potentiated this condition. The purpose of the report is to increase awareness of these rare but significant complications associated with anticonvulsants.
A 1966 journal article titled "The adult Fanconi syndrome" provides no specific patient data, treatment outcomes, or drug associations in the abstract. A 2021 abstract states that cystinosis is the most common cause of Fanconi syndrome in children. It describes cystinosis as a multi-systemic autosomal recessive lysosomal disease resulting from intracellular accumulation of cystine, characterised by proximal tubulopathy and corneal cystine crystals. Without treatment, the abstract says, cystinosis can lead to progressive renal damage, blindness, hypothyroidism, diabetes, and rickets.
No abstract reports a drug that reverses or cures Fanconi renotubular syndrome itself. The 1991 and 2012 reports describe drugs that caused the syndrome, not treatments for it. The 2021 abstract mentions cystinosis as the most common cause but does not describe any treatment. What is still missing is any controlled trial of a drug intended to treat the syndrome, any evidence that the underlying tubular defect can be repaired pharmacologically, and any patient stratification that might identify who could benefit from a given intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Hematology/Oncology · 1991 · 20 citations
Ifosfamide-Induced Fanconiʼs Syndrome with Growth Failure in a 2-Year-Old Child
AbstractFanconi's syndrome with phosphopenic rickets is described in a 2-year-old girl who had been treated for an embryonal sarcoma with multiagent chemotherapy including high-dose ifosfamide. The radiological and biochemical signs of rickets disappeared after treatment with 25-OH vitamin D3 and phosphorus supplements. Monitoring of tubular function in children during and after treatment with ifosfamide is mandatory.
BMJ Case Reports · 2012 · 10 citations · open access
Anticonvulsant-induced rickets and nephrocalcinosis
AbstractReported here is the case of a severely disabled young girl who developed Fanconi syndrome secondary to long-term valproic acid administration, ultimately leading to hypophosphatemic rickets. Although nephrocalcinosis is not a common feature in patients with proximal tubulopathy, the patient presented also with this condition, and the concomitant use of another anticonvulsant might have potentiated this condition. The purpose of this report is to increase awareness among healthcare providers of such rare but significant complications associated with anticonvulsants.
Postgraduate Medical Journal · 1966 · 2 citations · open access
The adult Fanconi syndrome
AbstractJournal Article The adult Fanconi syndrome Get access D P Mullan, MA, MB (Cantab) MRCP D P Mullan, MA, MB (Cantab) MRCP Medical Registrar Department of Medicine, The Royal Hospital, Sheffield Search for other works by this author on: Oxford Academic Google Scholar Postgraduate Medical Journal, Volume 42, Issue 483, January 1966, Pages 55–59, https://doi.org/10.1136/pgmj.42.483.55 Published: 01 January 1966
Kidney International Reports · 2021 · 0 citations · open access
POS-133 A CASE OF CORNEAL CYSTINOSIS IN A PATIENT WITH HEART ANS RENAL FAILURE
AbstractCystinosis is a multi systemic autosomal recessive lysosomal disease resulting from intracellular accumulation of cystine. The classic pediatric form is characterized by a proximal tubulopathy and corneal cystine crystals, This is the most common cause of Fanconi syndrome in children. Without treatment, cystinosis can also lead to progressive renal damage, blindness, hypothyroidism, diabetes and rickets.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
